{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:17Z","timestamp":1787166137662,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Painter Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcomatoid carcinoma of unknown primary (SCUP) is a rare entity of either poorly differentiated carcinoma with sarcoma-like differentiation or a true mixed lineage neoplasm. Limited data regarding clinicopathological profile and management exists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the MD Anderson Cancer of Unknown Primary database and tumor registry to identify 48 SCUP patients between 2001 and 2017. Patient characteristics, pathology, molecular diagnostics, treatments, and outcomes were obtained. Kaplan-Meier method was used to estimate overall survival (OS) and compared using log rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median age at diagnosis was 59\u2009years (range 27\u201386). Majority of patients were female (58%) and presented with \u22653 metastatic sites (52%), commonly lymph node (50%), bone (42%), lung (27%), and liver (21%). First line treatment included chemotherapy (35%), surgery (27%), and radiation (24%). Gemcitabine and docetaxel (18%) was the most common chemotherapy regimen. Median OS for entire cohort was 11\u2009months (95% CI: 5.6 to 16.4). Poor performance status (PS), &gt;\u20091 metastatic site, elevated lactate dehydrogenase (LDH), and high neutrophil-to-lymphocyte ratio (NLR) were significantly associated with worse OS on univariate analyses. On multivariate analyses, poor PS (HR 8.7; 95%CI: 3.0\u201325.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.001) and high NLR (HR 3.4; 95%CI: 1.3\u20138.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) emerged as independent prognostic factors for OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SCUP is a rare presentation with an aggressive clinical course and limited survival. Diagnosis is difficult to make and requires careful review and synthesis of histology, immunohistochemistry, and molecular diagnostics. Chemotherapy resistance remains a challenge. Early mutational profiling is warranted, and clinical trial participation should be encouraged for this subset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6155-6","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T07:32:48Z","timestamp":1571297568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait"],"prefix":"10.1186","volume":"19","author":[{"given":"Ryan W.","family":"Huey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Makawita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Matamoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannelyn S.","family":"Estrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri R.","family":"Varadhachary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"issue":"Suppl 1","key":"6155_CR1","doi-asserted-by":"publisher","first-page":"i75","DOI":"10.1093\/annonc\/mdi804","volume":"16","author":"E Briasoulis","year":"2005","unstructured":"Briasoulis E, Tolis C, Bergh J, Pavlidis N, Force EGT. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol. 2005;16(Suppl 1):i75\u20136 PubMed PMID: 15888766. Epub 2005\/05\/13.","journal-title":"Ann Oncol"},{"issue":"8","key":"6155_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371(8):757\u201365 PubMed PMID: 25140961. Epub 2014\/08\/21.","journal-title":"N Engl J Med"},{"issue":"3","key":"6155_CR3","doi-asserted-by":"publisher","first-page":"e5751","DOI":"10.1097\/MD.0000000000005751","volume":"96","author":"S Zhang","year":"2017","unstructured":"Zhang S, Jia J, Bi X, Jiang Q, Zhao Y, Chen Y, et al. Sarcomatoid carcinoma of the common bile duct: A case report. Medicine (Baltimore). 2017;96(3):e5751 PubMed PMID: 28099333. Pubmed Central PMCID: PMC5279078. Epub 2017\/01\/19.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"6155_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.humpath.2008.07.003","volume":"40","author":"X Wang","year":"2009","unstructured":"Wang X, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH, et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol. 2009;40(2):211\u20137 PubMed PMID: 18799188. Epub 2008\/09\/19.","journal-title":"Hum Pathol"},{"issue":"6","key":"6155_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420\u20138 PubMed PMID: 19487818. Pubmed Central PMCID: PMC2689101. Epub 2009\/06\/03.","journal-title":"J Clin Invest"},{"issue":"2","key":"6155_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1200\/JCO.2017.74.9523","volume":"36","author":"A Pang","year":"2018","unstructured":"Pang A, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and related cancers: tumors caught in the act of epithelial-mesenchymal transition. J Clin Oncol. 2018;36(2):210\u20136 PubMed PMID: 29220296. Epub 2017\/12\/09.","journal-title":"J Clin Oncol"},{"issue":"5","key":"6155_CR7","doi-asserted-by":"publisher","first-page":"e0154985","DOI":"10.1371\/journal.pone.0154985","volume":"11","author":"K Raghav","year":"2016","unstructured":"Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, et al. Cancer of unknown primary in adolescents and young adults: Clinicopathological features, prognostic factors and survival outcomes. PLoS One. 2016;11(5):e0154985 PubMed PMID: 27171493. Pubmed Central PMCID: 4865168.","journal-title":"PLoS One"},{"issue":"24","key":"6155_CR8","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1200\/JCO.2002.04.019","volume":"20","author":"S Culine","year":"2002","unstructured":"Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20(24):4679\u201383 PubMed PMID: 12488413.","journal-title":"J Clin Oncol"},{"issue":"2","key":"6155_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1008369812295","volume":"11","author":"FA Greco","year":"2000","unstructured":"Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11(2):211\u20135 PubMed PMID: 10761758. Epub 2000\/04\/13.","journal-title":"Ann Oncol"},{"issue":"3C","key":"6155_CR10","first-page":"2801","volume":"23","author":"D Pouessel","year":"2003","unstructured":"Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23(3C):2801\u20134 PubMed PMID: 12926116. Epub 2003\/08\/21.","journal-title":"Anticancer Res"},{"issue":"18","key":"6155_CR11","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1200\/JCO.2003.12.104","volume":"21","author":"S Culine","year":"2003","unstructured":"Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol. 2003;21(18):3479\u201382 PubMed PMID: 12972523. Epub 2003\/09\/16.","journal-title":"J Clin Oncol"},{"issue":"17","key":"6155_CR12","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2000.18.17.3101","volume":"18","author":"E Briasoulis","year":"2000","unstructured":"Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol. 2000;18(17):3101\u20137 PubMed PMID: 10963638. Epub 2000\/08\/30.","journal-title":"J Clin Oncol"},{"issue":"12","key":"6155_CR13","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1097\/JTO.0b013e3181f387e4","volume":"5","author":"DS O\u2019Callaghan","year":"2010","unstructured":"O\u2019Callaghan DS, O\u2019Donnell D, O\u2019Connell F, O\u2019Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024\u201336 PubMed PMID: 21155185. Epub 2010\/12\/16.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"6155_CR14","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124 PubMed PMID: 24875653. Epub 2014\/05\/31.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6155_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s12032-013-0556-1","volume":"30","author":"M Kobayashi","year":"2013","unstructured":"Kobayashi M, Kubo T, Komatsu K, Fujisaki A, Terauchi F, Natsui S, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30(2):556 PubMed PMID: 23539200. Epub 2013\/03\/30.","journal-title":"Med Oncol"},{"issue":"10","key":"6155_CR16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ejso.2018.04.022","volume":"44","author":"T Abe","year":"2018","unstructured":"Abe T, Amano H, Kobayashi T, Hanada K, Nakahara M, Ohdan H, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2018;44(10):1573\u20139 PubMed PMID: 29807728. Epub 2018\/05\/29.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"6155_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/annonc\/mdu587","volume":"26","author":"D Lorente","year":"2015","unstructured":"Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26(4):750\u20135 PubMed PMID: 25538172. Epub 2014\/12\/30.","journal-title":"Ann Oncol"},{"issue":"11","key":"6155_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s12094-012-0872-5","volume":"14","author":"S Cedres","year":"2012","unstructured":"Cedres S, Torrejon D, Martinez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864\u20139 PubMed PMID: 22855161. Epub 2012\/08\/03.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"6155_CR19","doi-asserted-by":"publisher","first-page":"e0193018","DOI":"10.1371\/journal.pone.0193018","volume":"13","author":"T Kiriu","year":"2018","unstructured":"Kiriu T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018;13(2):e0193018 PubMed PMID: 29447258. Pubmed Central PMCID: PMC5814002. Epub 2018\/02\/16.","journal-title":"PLoS One"},{"issue":"2","key":"6155_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.humpath.2013.09.005","volume":"45","author":"SB Terra","year":"2014","unstructured":"Terra SB, Aubry MC, Yi ES, Boland JM. Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma--sensitivity of TTF-1 is superior to napsin. Hum Pathol. 2014;45(2):294\u2013302 PubMed PMID: 24331839. Epub 2013\/12\/18.","journal-title":"Hum Pathol"},{"issue":"7","key":"6155_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ctrv.2015.05.010","volume":"41","author":"P Economopoulou","year":"2015","unstructured":"Economopoulou P, Mountzios G, Pavlidis N, Pentheroudakis G. Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer. Cancer Treat Rev. 2015;41(7):598\u2013604 PubMed PMID: 26033502. Epub 2015\/06\/03.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"6155_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","volume":"1","author":"JS Ross","year":"2015","unstructured":"Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40\u20139 PubMed PMID: 26182302. Epub 2015\/07\/17.","journal-title":"JAMA Oncol"},{"issue":"6349","key":"6155_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313 PubMed PMID: 28596308. Pubmed Central PMCID: PMC5576142. Epub 2017\/06\/10.","journal-title":"Science"},{"issue":"14","key":"6155_CR24","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/0008-5472.CAN-08-2819","volume":"69","author":"T Arumugam","year":"2009","unstructured":"Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820\u20138 PubMed PMID: 19584296. Pubmed Central PMCID: PMC4378690.","journal-title":"Cancer Res"},{"issue":"2","key":"6155_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2011.11.142","volume":"417","author":"W Zhang","year":"2012","unstructured":"Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417(2):679\u201385 PubMed PMID: 22166209.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"6155_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tips.2014.06.006","volume":"35","author":"FM Davis","year":"2014","unstructured":"Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35(9):479\u201388 PubMed PMID: 25042456.","journal-title":"Trends Pharmacol Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6155-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6155-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6155-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T19:19:07Z","timestamp":1602789547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6155-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6155"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6155-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"27 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee at MD Anderson Cancer Center. A waiver for informed consent was granted since this retrospective analysis involved no more than minimal risk to the subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"965"}}